ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the third leading cause of cancer-related mortality within the next decade. Management of PDAC remains challenging

with limited effective treatment options and a dismal long-term prognosis. Liquid biopsy and circulating biomarkers seem to be promising to improve the multidisciplinary approach in PDAC

treatment. Circulating tumour DNA (ctDNA) is the most studied blood liquid biopsy analyte and can provide insight into the molecular profile and individual characteristics of the tumour in

real-time and in advance of standard imaging modalities. This could pave the way for identifying new therapeutic targets and markers of tumour response to supplement diagnostic and provide

review explores the current knowledge and recent developments in ctDNA as a screening, diagnostic, prognostic and predictive biomarker in the management of resectable PDAC but also technical

and analytical challenges that must be overcome to move toward “precision onco-surgery.” Access through your institution Buy or subscribe This is a preview of subscription content, access

via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy

this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *

Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS CIRCULATING TUMOUR CELLS AS AN INDICATOR OF EARLY AND

SYSTEMIC RECURRENCE AFTER SURGICAL RESECTION IN PANCREATIC DUCTAL ADENOCARCINOMA Article Open access 18 January 2021 LIQUID BIOPSIES TO MONITOR AND DIRECT CANCER TREATMENT IN COLORECTAL

CANCER Article Open access 09 March 2022 CIRCULATING TUMOR DNA IN MOLECULAR ASSESSMENT FEASIBLY PREDICTS EARLY PROGRESSION OF PANCREATIC CANCER THAT CANNOT BE IDENTIFIED VIA INITIAL IMAGING

Article Open access 23 March 2023 REFERENCES * Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and

mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article  PubMed  Google Scholar  * Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer:

global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. Article  PubMed  PubMed Central  Google Scholar  * Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer

than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158–60. Article  CAS  PubMed  Google Scholar  * Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin.

2020;70:7–30. Article  PubMed  Google Scholar  * Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.

N Engl J Med. 2018;379:2395–406. Article  CAS  PubMed  Google Scholar  * Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of

pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105–19. CAS  PubMed  PubMed Central  Google Scholar  * Goggins M. Molecular markers of early pancreatic

cancer. J Clin Oncol. 2005;23:4524–31. Article  CAS  PubMed  Google Scholar  * Kondo N, Murakami Y, Uemura K, Nakagawa N, Takahashi S, Ohge H, et al. Comparison of the prognostic impact of

pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Pancreatology. 2017;17:95–102. Article  CAS  PubMed  Google Scholar  * Ishii H, Okada S,

Sato T, Wakasugi H, Saisho H, Furuse J, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepato Gastroenterol. 1997;44:279–83. CAS  Google Scholar  *

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.

Article  CAS  PubMed  Google Scholar  * Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312.

Article  PubMed  Google Scholar  * Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909. Article  CAS  PubMed  Google Scholar  * Bailey P, Chang

DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52. Article  CAS  PubMed  Google Scholar  * Bournet

B, Buscail C, Muscari F, Cordelier P, Buscail L. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities. Eur J Cancer. 2016;54:75–83. Article  CAS

  PubMed  Google Scholar  * Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157–88. Article  CAS  PubMed  PubMed Central  Google Scholar  * Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS:

feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91–100. Article  CAS  PubMed  PubMed Central  Google Scholar  * Hruban RH, Maitra A, Schulick R, Laheru D, Herman J, Kern

SE, et al. Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2008;2(Suppl):S10–5. PubMed  PubMed Central  Google Scholar  * Waddell N, Pajic M, Patch AM, Chang DK,

Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501. Article  CAS  PubMed  PubMed Central  Google Scholar  * Puleo F,

Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 2018;155:1999–2013

e3. Article  PubMed  Google Scholar  * Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer Genome Atlas Research N. Integrated Genomic Characterization of Pancreatic

Ductal Adenocarcinoma. Cancer Cell. 2017;32:185–203 e13. Article  CAS  Google Scholar  * de Santiago I, Yau C, Heij L, Middleton MR, Markowetz F, Grabsch HI, et al. Immunophenotypes of

pancreatic ductal adenocarcinoma: meta-analysis of transcriptional subtypes. Int J Cancer. 2019;145:1125–37. Article  CAS  PubMed  PubMed Central  Google Scholar  * Sausen M, Phallen J,

Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686. Article 

PubMed  Google Scholar  * Sugimori M, Sugimori K, Tsuchiya H, Suzuki Y, Tsuyuki S, Kaneta Y, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic

cancer undergoing chemotherapy. Cancer Sci. 2020;111:266–78. Article  CAS  PubMed  Google Scholar  * Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, et al. Cell-free DNA

next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5:1040–8. Article  CAS  PubMed  PubMed Central  Google Scholar  * Shapiro B, Chakrabarty M, Cohn EM, Leon SA.

Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51:2116–20. Article  CAS  PubMed  Google Scholar  * Diaz LA Jr., Bardelli

A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86. Article  PubMed  PubMed Central  Google Scholar  * Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun

M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–76. Article  CAS  PubMed  PubMed Central  Google Scholar  * Jeppesen DK, Fenix AM,

Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019;177:428–45.e18. Article  CAS  PubMed  PubMed Central  Google Scholar  * Yong E.

Cancer biomarkers: written in blood. Nature. 2014;511:524–6. Article  CAS  PubMed  Google Scholar  * Taly V, Pekin D, El Abed A, Laurent-Puig P. Detecting biomarkers with microdroplet

technology. Trends Mol Med. 2012;18:405–16. Article  CAS  PubMed  Google Scholar  * Pecuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, et al. Base-position error rate analysis

of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med. 2016;13:e1002199. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Newman AM, Bratman SV, Wynne J, Eclov JF, Modlin NC. LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med.

2014;20:548–54. * Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat

Biotechnol. 2016;34:547–55. Article  CAS  PubMed  PubMed Central  Google Scholar  * Dabritz J, Preston R, Hanfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients

with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009;38:534–41. Article  CAS  PubMed  Google Scholar  * Maire F, Micard S, Hammel P,

Voitot H, Levy P, Cugnenc PH, et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer.

2002;87:551–4. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, et al. Detection of K-ras gene mutation by liquid

biopsy in patients with pancreatic cancer. Cancer. 2015;121:2271–80. Article  CAS  PubMed  Google Scholar  * Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, et al. Clinical

utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015;5:18425. Article  CAS  PubMed  PubMed Central  Google Scholar  * Hadano N, Murakami Y, Uemura K,

Hashimoto Y, Kondo N, Nakagawa N, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115:59–65. * Pietrasz

D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23:116–23. Article 

CAS  PubMed  Google Scholar  * Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodriguez-Garrote M, et al. Circulating tumor cells (Ctc) and kras mutant circulating

free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Buscail E, Chauvet A, Quincy P, Degrandi O, Buscail C, Lamrissi I, et al. CD63-GPC1-positive exosomes coupled with CA19-9 offer good diagnostic potential for resectable pancreatic

ductal adenocarcinoma. Transl Oncol. 2019;12:1395–403. Article  PubMed  PubMed Central  Google Scholar  * Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, et al. KRAS

mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7:78827–40. Article  PubMed  PubMed Central  Google Scholar  * Van Paemel R, De Koker A,

Caggiano C, Morlion A, Mestdagh P, De Wilde B, et al. Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. Epigenetics. 2020:16;797–807. * Greytak SR,

Engel KB, Parpart-Li S, Murtaza M, Bronkhorst AJ, Pertile MD, et al. Harmonizing cell-free DNA collection and processing practices through evidence-based guidance. Clin Cancer Res.

2020;26:3104–9. Article  CAS  PubMed  PubMed Central  Google Scholar  * Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, et al. Promoter methylation of ADAMTS1 and BNC1 as

potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11:59. Article  CAS  PubMed  PubMed Central  Google Scholar  * Singh N, Rashid S, Rashid S,

Dash NR, Gupta S, Saraya A. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients. J Cancer Res Clin Oncol.

2020;146:897–907. Article  CAS  PubMed  Google Scholar  * Feinberg AP, Cui H, Ohlsson R. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer

Biol. 2002;12:389–98. Article  CAS  PubMed  Google Scholar  * Liggett T, Melnikov A, Yi Q-l, Replogle C, Brand R, Kaul K, et al. Differential methylation of cell-free circulating DNA among

patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010;116:1674–80. Article  CAS  PubMed  Google Scholar  * Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV.

Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009;99:119–22. Article  PubMed  Google Scholar  * Henriksen SD, Madsen PH, Larsen AC,

Johansen MB, Pedersen IS, Krarup H, et al. Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. Oncotarget.

2017;8:93942–56. Article  PubMed  PubMed Central  Google Scholar  * Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, et al. Leukocyte DNA methylation signature

differentiates pancreatic cancer patients from healthy controls. PLoS ONE. 2011;6:e18223. Article  CAS  PubMed  PubMed Central  Google Scholar  * Majumder S, Taylor W, Foote PH, Berger CK,

Wu CW, Mahoney DW, et al. High detection rates of pancreatic cancer across stages by plasma assay of novel methylated DNA markers and CA 19-9. Clin Cancer Res. 2021;27:2523–32. * Yachida S,

Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, et al. A combination of molecular markers and clinical features improve the classification of

pancreatic cysts. Gastroenterology. 2015;149:1501–10. Article  CAS  PubMed  Google Scholar  * Singhi AD, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, et al. Preoperative

next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2018;67:2131–41. Article  CAS  PubMed  Google Scholar

  * Berger AW, Schwerdel D, Costa IG, Hackert T, Strobel O, Lam S, et al. Detection of hot-spot mutations in circulating cell-free DNA from patients with intraductal papillary mucinous

neoplasms of the pancreas. Gastroenterology. 2016;151:267–70. Article  CAS  PubMed  Google Scholar  * Hata T, Mizuma M, Motoi F, Omori Y, Ishida M, Nakagawa K, et al. GNAS mutation detection

in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype. Sci Rep. 2020;10:17761. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S, et al. Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers.

2019;11;852. * Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic

cancers. Proc Natl Acad Sci USA. 2017;114:10202–7. Article  CAS  PubMed  PubMed Central  Google Scholar  * Guo S, Shi X, Shen J, Gao S, Wang H, Shen S, et al. Preoperative detection of KRAS

G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Br J Cancer. 2020;122:857–67. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann

Oncol. 2017;28:741–7. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kato S, Honda K. Use of biomarkers and imaging for early detection of pancreatic cancer. Cancers. 2020;12:1965.

* Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature.

2018;563:579–83. Article  CAS  PubMed  Google Scholar  * Fujimoto Y, Suehiro Y, Kaino S, Suenaga S, Tsuyama T, Matsui H, et al. Combination of CA19-9 and blood free-circulating methylated

RUNX3 may be useful to diagnose stage I pancreatic cancer. Oncology. 2021;99:234–9. Article  CAS  PubMed  Google Scholar  * Shinjo K, Hara K, Nagae G, Umeda T, Katsushima K, Suzuki M, et al.

A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. PLoS ONE. 2020;15:e0233782. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30. Article

  CAS  PubMed  PubMed Central  Google Scholar  * Delpero JR, Sauvanet A. Vascular resection for pancreatic cancer: 2019 French Recommendations Based on a Literature Review From 2008 to

6-2019. Front Oncol. 2020;10:40. Article  PubMed  PubMed Central  Google Scholar  * Cassinotto C, Cortade J, Belleannee G, Lapuyade B, Terrebonne E, Vendrely V, et al. An evaluation of the

accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol. 2013;82:589–93. Article  PubMed  Google Scholar  * Ferrone CR,

Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline

resectable pancreatic cancer. Ann Surg. 2015;261:12–7. Article  PubMed  Google Scholar  * Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, et al. CT evaluation after

neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;27:3104–16. Article  PubMed  Google Scholar  * Bettegowda C, Sausen M,

Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for

localized pancreatic cancer. Ann Oncol. 2019;30:1472–8. Article  CAS  PubMed  PubMed Central  Google Scholar  * Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. Article  CAS  PubMed  Google Scholar  * Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante

J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. Article  CAS  Google Scholar  * Groot VP, Mosier S, Javed

AA, Teinor JA, Gemenetzis G, Ding D, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res. 2019;25:4973–84. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Nakano Y, Kitago M, Matsuda S, Nakamura Y, Fujita Y, Imai S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker:

a retrospective study. Br J Cancer. 2018;118:662–9. Article  CAS  PubMed  PubMed Central  Google Scholar  * Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, et al. Longitudinal

monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE. 2019;14:e0227366. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Mohan S, Ayub M, Rothwell DG, Gulati S, Kilerci B, Hollebecque A, et al. Analysis of circulating cell-free DNA identifies KRAS copy number gain and

mutation as a novel prognostic marker in Pancreatic cancer. Sci Rep. 2019;9:11610. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kim MK, Woo SM, Park B, Yoon KA, Kim YH, Joo J, et

al. Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma. Clin Chem. 2018;64:726–34. Article  CAS  PubMed 

Google Scholar  * Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol.

2019;12:130. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang SE, Shyr BU, Shyr BS, Chen SC, Chang SC, Shyr YM. Circulating cell-free DNA in pancreatic head adenocarcinoma

undergoing pancreaticoduodenectomy. Pancreas. 2021;50:214–8. Article  CAS  PubMed  Google Scholar  * Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, et al. Repeated mutKRAS ctDNA

measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29:2348–55. Article  CAS  PubMed 

Google Scholar  * Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in

metastatic pancreatic ductal adenocarcinoma. International journal of cancer. J Int du Cancer. 2020;146:1445–56. Article  CAS  Google Scholar  * Yamaguchi T, Uemura K, Murakami Y, Kondo N,

Nakagawa N, Okada K, et al. Clinical implications of pre- and postoperative circulating tumor DNA in patients with resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2021;28:3135–44.

* Hussung S, Akhoundova D, Hipp J, Follo M, Klar RFU, Philipp U, et al. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of

pancreatic cancer. BMC Cancer. 2021;21:49. Article  CAS  PubMed  PubMed Central  Google Scholar  * Chen K, Sun J, Zhao H, Jiang R, Zheng J, Li Z, et al. Non-invasive lung cancer diagnosis

and prognosis based on multi-analyte liquid biopsy. Mol Cancer. 2021;20:23. Article  PubMed  PubMed Central  Google Scholar  * Hofmann L, Sallinger K, Haudum C, Smolle M, Heitzer E, Moser T,

et al. A multi-analyte approach for improved sensitivity of liquid biopsies in prostate cancer. Cancers. 2020;12;2247. * Buscail E, Alix-Panabières C, Quincy P, Cauvin T, Chauvet A,

Degrandi O, et al. High clinical value of liquid biopsy to detect circulating tumor cells and tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front surgery.

Cancers. 2019;11:1656. * Lee B. Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (DYNAMIC- Pancreas): ANZCTR.

2018. https://anzctr.org.au/ACTRN12618000335291.aspx. Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * APHP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Université

Paris-Saclay, 94800, Villejuif, France Daniel Pietrasz * Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, Verona, Italy Daniel

Pietrasz, Elisabetta Sereni, Francesco Lancelotti, Antonio Pea, Giulio Innamorati, Roberto Salvia & Claudio Bassi * Department of Diagnostics and Public Health, Section of Pathology,

University and Hospital Trust of Verona, Verona, Italy Claudio Luchini Authors * Daniel Pietrasz View author publications You can also search for this author inPubMed Google Scholar *

Elisabetta Sereni View author publications You can also search for this author inPubMed Google Scholar * Francesco Lancelotti View author publications You can also search for this author

inPubMed Google Scholar * Antonio Pea View author publications You can also search for this author inPubMed Google Scholar * Claudio Luchini View author publications You can also search for

this author inPubMed Google Scholar * Giulio Innamorati View author publications You can also search for this author inPubMed Google Scholar * Roberto Salvia View author publications You can

also search for this author inPubMed Google Scholar * Claudio Bassi View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Conception/design of

the work: DP, AP, RS, CB. Literature review: DP, ES, FL. Analysis of the selected data: DP, ES, FL, AP. Drafting the work: DP, ES, FL, AP, CL, RS, CB. Revising it critically: all. Final

approval of the version to be published: all. CORRESPONDING AUTHOR Correspondence to Daniel Pietrasz. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests.

ETHIC APPROVAL Not applicable. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Pietrasz, D., Sereni, E., Lancelotti, F. _et al._ Circulating tumour DNA: a challenging innovation to

develop “precision onco-surgery” in pancreatic adenocarcinoma. _Br J Cancer_ 126, 1676–1683 (2022). https://doi.org/10.1038/s41416-022-01745-2 Download citation * Received: 22 June 2021 *

Revised: 13 December 2021 * Accepted: 04 February 2022 * Published: 23 February 2022 * Issue Date: 01 June 2022 * DOI: https://doi.org/10.1038/s41416-022-01745-2 SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative